171 related articles for article (PubMed ID: 34134020)
21. The pathophysiology of bilateral and multifocal Wilms tumors: What we can learn from the study of predisposition syndromes.
Welter N; Brzezinski J; Treece A; Chintagumpala M; Young MD; Perotti D; Kieran K; Jongmans MCJ; Murphy AJ
Pediatr Blood Cancer; 2023 May; 70 Suppl 2():e29984. PubMed ID: 36094328
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of age in 5631 patients with Wilms tumour prospectively registered in International Society of Paediatric Oncology (SIOP) 93-01 and 2001.
Hol JA; Lopez-Yurda MI; Van Tinteren H; Van Grotel M; Godzinski J; Vujanic G; Oldenburger F; De Camargo B; Ramírez-Villar GL; Bergeron C; Pritchard-Jones K; Graf N; Van den Heuvel-Eibrink MM
PLoS One; 2019; 14(8):e0221373. PubMed ID: 31425556
[TBL] [Abstract][Full Text] [Related]
23. The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT 2001 trial.
Jackson TJ; Williams RD; Brok J; Chowdhury T; Ronghe M; Powis M; Pritchard-Jones K; Vujanić GM;
Pediatr Blood Cancer; 2019 Jun; 66(6):e27627. PubMed ID: 30761727
[TBL] [Abstract][Full Text] [Related]
24. Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG).
Green DM
Eur J Cancer; 2015 May; 51(8):993-4. PubMed ID: 25818548
[No Abstract] [Full Text] [Related]
25. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol.
van den Heuvel-Eibrink MM; Hol JA; Pritchard-Jones K; van Tinteren H; Furtwängler R; Verschuur AC; Vujanic GM; Leuschner I; Brok J; Rübe C; Smets AM; Janssens GO; Godzinski J; Ramírez-Villar GL; de Camargo B; Segers H; Collini P; Gessler M; Bergeron C; Spreafico F; Graf N;
Nat Rev Urol; 2017 Dec; 14(12):743-752. PubMed ID: 29089605
[TBL] [Abstract][Full Text] [Related]
26. Rarity of surgical complications after postchemotherapy nephrectomy for nephroblastoma. Experience of the International Society of Paediatric Oncology-Trial and Study "SIOP-9". International Society of Paediatric Oncology Nephroblastoma Trial and Study Committee.
Godzinski J; Tournade MF; deKraker J; Lemerle J; Voute PA; Weirich A; Ludwig R; Rapala M; Skotnicka G; Gauthier F; Moorman-Voestermans CG; Buerger D; VanVeen A; Sawicz-Birkowska K
Eur J Pediatr Surg; 1998 Apr; 8(2):83-6. PubMed ID: 9617606
[TBL] [Abstract][Full Text] [Related]
27. Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.
Chagtai T; Zill C; Dainese L; Wegert J; Savola S; Popov S; Mifsud W; Vujanić G; Sebire N; Le Bouc Y; Ambros PF; Kager L; O'Sullivan MJ; Blaise A; Bergeron C; Mengelbier LH; Gisselsson D; Kool M; Tytgat GA; van den Heuvel-Eibrink MM; Graf N; van Tinteren H; Coulomb A; Gessler M; Williams RD; Pritchard-Jones K
J Clin Oncol; 2016 Sep; 34(26):3195-203. PubMed ID: 27432915
[TBL] [Abstract][Full Text] [Related]
28. Minichromosome maintenance 2 (MCM2) is a new prognostic proliferative marker in Wilms tumour.
Taran K; Sitkiewicz A; Andrzejewska E; Kobos J
Pol J Pathol; 2011; 62(2):84-8. PubMed ID: 21866463
[TBL] [Abstract][Full Text] [Related]
29. Central pathology review in multicenter trials and studies: lessons from the nephroblastoma trials.
Vujanić GM; Sandstedt B; Kelsey A; Sebire NJ
Cancer; 2009 May; 115(9):1977-83. PubMed ID: 19241454
[TBL] [Abstract][Full Text] [Related]
30. Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma.
Kalish JM; Doros L; Helman LJ; Hennekam RC; Kuiper RP; Maas SM; Maher ER; Nichols KE; Plon SE; Porter CC; Rednam S; Schultz KAP; States LJ; Tomlinson GE; Zelley K; Druley TE
Clin Cancer Res; 2017 Jul; 23(13):e115-e122. PubMed ID: 28674120
[TBL] [Abstract][Full Text] [Related]
31. SIOP treatment guidelines for renal tumours in small infants: fact or fantasy?
Levie NS; de Kraker J; Bökkerink JP; Appel IM; Aronson DC
Eur J Surg Oncol; 2000 Sep; 26(6):567-70. PubMed ID: 11034807
[TBL] [Abstract][Full Text] [Related]
32. Tumour lysis syndrome as a rare complication of chemotherapy in paediatric Wilms' Tumour: a case report.
Qamar S; Sindhu II; Shaheen N
J Pak Med Assoc; 2023 Mar; 73(3):700-704. PubMed ID: 36932788
[TBL] [Abstract][Full Text] [Related]
33. Is radiotherapy required in first-line treatment of stage I diffuse anaplastic Wilms tumor? A report of SIOP-RTSG, AIEOP, JWiTS, and UKCCSG.
Fajardo RD; van den Heuvel-Eibrink MM; van Tinteren H; Spreafico F; Acha T; Bergeron C; de Camargo B; Oldenburger F; Rübe C; Oue T; Vokuhl C; de Krijger RR; Vujanic G; Sebire N; Coulomb-L'Hermine A; Collini P; Gandola L; Pritchard-Jones K; Graf N; Janssens GO; van Grotel M
Pediatr Blood Cancer; 2020 Feb; 67(2):e28039. PubMed ID: 31625685
[TBL] [Abstract][Full Text] [Related]
34. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
35. Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
; van den Heuvel-Eibrink MM; Pritchard-Jones K; van Tinteren H; Graf N
Eur J Cancer; 2015 May; 51(8):995-6. PubMed ID: 25840668
[No Abstract] [Full Text] [Related]
36. [Wilms' tumour of unfavorable histology--results of treatment with the SIOP 93-01 protocol at the Gdańsk centre. Preliminary report].
Stefanowicz J; Sierota D; Balcerska A; Stoba C
Med Wieku Rozwoj; 2004; 8(2 Pt 1):197-200. PubMed ID: 15738594
[TBL] [Abstract][Full Text] [Related]
37. 16q heterozygosity loss in Wilms' tumour in children and its clinical importance.
Skotnicka-Klonowicz G; Rieske P; Bartkowiak J; Szymik-Kantorowicz S; Daszkiewicz P; Debiec-Rychter M
Eur J Surg Oncol; 2000 Feb; 26(1):61-6. PubMed ID: 10718182
[TBL] [Abstract][Full Text] [Related]
38. Wilms tumour: prognostic factors, staging, therapy and late effects.
Kaste SC; Dome JS; Babyn PS; Graf NM; Grundy P; Godzinski J; Levitt GA; Jenkinson H
Pediatr Radiol; 2008 Jan; 38(1):2-17. PubMed ID: 18026723
[TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
[TBL] [Abstract][Full Text] [Related]
40. Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice.
Scott RH; Walker L; Olsen ØE; Levitt G; Kenney I; Maher E; Owens CM; Pritchard-Jones K; Craft A; Rahman N
Arch Dis Child; 2006 Dec; 91(12):995-9. PubMed ID: 16857697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
